NVAXHealthcare · BiotechnologyThe 9 Wall Street analysts covering Novavax, Inc. hold a median 12-month price target of $16 — +50.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 61 of 100 as at 3 Nov 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Novavax, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (17): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on NVAX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +50.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 Oct 2026 | Citigroup | Maintains | Sell | $7.00 → $8.00 |
| 11 June 2026 | BTIG | Reiterates | Buy | $19 |
| 11 June 2026 | BTIG | Reiterates | Buy | — |
| 6 May 2026 | TD Cowen | Maintains | Hold | — |
| 27 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 Jan 2026 | BTIG | Reiterates | Buy | — |
| 18 Nov 2025 | JP Morgan | Maintains | Underweight | — |
| 10 Nov 2025 | B. Riley Securities | Reiterates | Buy | — |
| 4 Nov 2025 | TD Cowen | Maintains | Hold | — |
| 24 Oct 2025 | Cantor Fitzgerald | Initiates | Overweight | — |
| 23 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 28 Aug 2025 | HC Wainwright & Co. | Assumes | Buy | $10 |
| 20 Aug 2025 | B of A Securities | Downgrade | Underperform | — |
| 22 July 2025 | B of A Securities | Maintains | Neutral | — |
| 17 June 2025 | Citigroup | Initiates | Sell | — |
| 9 May 2025 | JP Morgan | Maintains | Underweight | — |
| 10 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Oct 2024 | Jefferies | Maintains | Buy | $31 → $25 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
NVAX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Novavax, Inc. returned +41.9% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 67% of US stocks
Cheaper than 30% of US stocks
Cheaper than 98% of US stocks
Cheaper than 86% of US stocks
Higher than 3% of US stocks
Higher than 6% of US stocks
Higher than 87% of US stocks
Higher than 14% of US stocks
Higher than 9% of US stocks
Higher than 5% of US stocks
Higher than 30% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Novavax, Inc. has a market value of $1.6B and an enterprise value of $1.2B.
Revenue in the twelve months to 30 June 2026: $413.8M. The latest quarter shrank 76.3% year on year.
Net income over the same four quarters: −$247.7M, a −59.9% net margin.
Diluted earnings per share, trailing twelve months: $−1.52.
Free cash flow in the twelve months to 30 June 2026: −$43.0M, after $5.3M of capital spending.
Trailing P/E: 3.6×; forward P/E: −59.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Novavax, Inc. employs 749 people — $552K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Novavax, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research says Novavax lacks the combination of factors it associates with a likely earnings beat ahead of its Q3 report, and flags the possibility of negative earnings.
Why it matters — NVAX watchers may view the item as context on expectations going into the company's Q3 earnings release.
Novavax earned a $125 million milestone payment after Sanofi initiated its Phase 3 influenza-COVID-19 combination vaccine trial in Europe, with the fifth patient dosed. The candidate combines Sanofi’s high-dose flu vaccine with Novavax’s Nuvaxovid.
Why it matters — The payment marks a partnership milestone, and the excerpt notes potential for additional future milestones and royalties.
Novavax announced that it plans to release its third-quarter 2026 financial results before U.S. markets open on November 5, 2026.
Why it matters — NVAX watchers may note the scheduled date and timing for the company’s quarterly results release.
Moderna shares rose 4% as investors weighed strong cancer vaccine data against valuation concerns, despite a William Blair downgrade. Novavax and BioNTech shares also edged higher, according to the headline.
Why it matters — The report notes Novavax moved higher alongside Moderna and BioNTech, placing its shares in the same market update.
Novavax (NVAX) closed the recent trading session at $9.40, down 3.09% from the prior day's close, despite an uptick in the broader market.
Why it matters — The session's decline gives NVAX watchers a snapshot of the stock's recent performance relative to the market's direction.
The 9 Wall Street analysts covering Novavax, Inc. have a median 12-month price target of $16, with estimates ranging from $7 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Novavax, Inc., 5 rate it a Buy, 1 a Hold and 3 a Sell. Ticker Nerd's systematic factor model ranks Novavax, Inc. 61 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, Novavax, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +50.1% from the last close, and Ticker Nerd's factor model ranks Novavax, Inc. 61 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Novavax, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NVAX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $25 over the next 12 months.
Novavax, Inc. returned +41.9% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Novavax Inc. is a biotechnology company focused on developing and commercializing vaccines that address serious infectious diseases.
The most recent item we track (Zacks Investment Research, 29 Oct 2026): "Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release". Zacks Investment Research says Novavax lacks the combination of factors it associates with a likely earnings beat ahead of its Q3 report, and flags the possibility of negative earnings.
Novavax Inc. is a biotechnology company focused on developing and commercializing vaccines that address serious infectious diseases. Novavax Inc. uses a proprietary recombinant protein platform paired with its Matrix-M adjuvant technology to support immune responses across its vaccine portfolio. Its current products and programs include COVID-19 vaccines marketed under the Nuvaxovid brand and the R21/Matrix-M malaria vaccine, along with research efforts aimed at additional infectious disease targets. The company serves global public health markets through vaccine development, manufacturing, and commercialization activities, and it also works with partners and institutions involved in vaccine supply and distribution. Headquartered in Gaithersburg, Maryland, Novavax Inc. remains recognized for its vaccine-focused business model and its role in advancing protein-based immunization technologies.
CEO Mr. John Charles Jacobs M.B.A. · 749 employees · United States · https://www.novavax.com
